drugset / Trial / NCT05015621
A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy of Surufatnib combined with Toripalimab compared with FOLFIRI in the treatment of advanced neuroendocrine carcinoma
Timeline
- Start
- 2021-09-18
- Primary completion
- 2025-05-31
- Completion
- 2025-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Comparator | Surufatinib | Small molecule | 250 mg | Oral |
| Comparator | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | fluorouracil | Small molecule | 2800 mg/m2 | Intravenous |